PTO/SB/21 (07-09)

Under the Paperworl	k Reduction Act of 1995, no pers	ons are required to res	U.S. Patent and Tradem	oved for use through 07/3/1/2012.  OMB 0651-00 nark Office;  U.S. DEPARTMENT OF COMMER( nation unless it displays a valid OMB control numb		
			Application Number	10/595,230-Conf. #5170		
TRANSMITTAL FORM			Filing Date	March 28, 2006		
			First Named Inventor	Kyle J. Lindstrom		
		:	Art Unit	1625		
(to be used for all correspondence after initial filing)			Examiner Name	R. J. Desai		
Total Number of Pages in This Submission			Attorney Docket Numb	C1271.70017US01		
ENCLOSURES (Check all that apply)						
Fee Trans	mittal Form	Drawing(s)	· · · · · · · · · · · · · · · · · · ·	After Allowance Communication		
│ │ │ □	A441		ata d Danasa	to TC Appeal Communication to Board		
Fee Attached		Licensing-related Papers		of Appeals and Interferences		
Amendment/Reply		Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final		Petition to Convert to a Provisional Application		Proprietary Information		
Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address		Status Letter		
Extension	of Time Request	Terminal Disclaimer		X Other Enclosure(s) (please Identify below):		
Express Abandonment Request		Request for Refund		Form PTO-1449		
x Information Disclosure Statement		CD, Number of CD(s)				
Certified Copy of Priority Document(s)		Landscape Table on CD				
	/lissing Parts/ e Application	Remarks				
	ly to Missing Parts under CFR 1.52 or 1.53					
	71 (1.52 0) 1.50					
	SIGNAT	URE OF APPLIC	ANT, ATTORNEY, O	R AGENT		
Firm Name	WOLF, GREENFIELD & SACKS, P.C.					
Signature	C743	26				
Printed name	C. Hunter Baker, M.	D., Ph.D.				
Date	11/10/2009		Reg. No.	46,533		

ate of Electronic Filing Under 37 CFR 1.8 erred to as being attached or enclosed) is being transmitted via the Office electronic filing  Signature: Signat

DOCKET NO.: C1271.70017US01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Kyle J. Lindstrom et al.

Serial No.:

10/595,230

Confirmation No.:

5170

Filed:

March 28, 2006

For:

ALKOXY SUBSTITUTED IMIDAZOQUINOLINES

Examiner:

Rita J. Desai

Art Unit:

1625

Certificate of Electronic Filing Under 37 CFR 1.8

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: 11 10 09

Sara J. L. Bouglas

# STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

# PART I: Compliance with 37 C.F.R. § 1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office Action, but before the mailing date of any final action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution in this application.

The Applicant hereby states, as specified in 37 C.F.R. § 1.97(e), that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart for this application not more than three months prior to the filing of this Statement. Therefore, no fee is required.

Serial No.: 10/595,230 - 2 - Art Unit: 1625

Conf. No.: 5170

## PART II: Compliance with 37 CFR § 1.704(d)

Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by the office of the undersigned more than thirty (30) days prior to the filing of this Information Disclosure Statement.

#### PART III: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

#### PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

Serial No.: 10/595,230 - 3 - Art Unit: 1625

Conf. No.: 5170

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:

C. Hunter Baker, M.D., Ph.D.,

Reg. No. 46,533

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: C1271.70017US01 Date: November \_/0, 2009

x12/03/09x